Breaking AI & Tech News Analyzed

The Sydney Kings secured their sixth NBL championship after a dramatic 113‑101 overtime victory over the Adelaide 36ers in the decisive fifth game of the series.In front of a record‑breaking crowd of 18,589 spectators at the Sydney venue on Easter Sunday, Kings guard Kendric Davis delivered a stellar performance, tallying 35 points and 14 assists, which earned him the series MVP honor.Adelaide’s star guard Bryce Cotton matched Davis with 35 points, fueling a fierce duel that defined the series and kept the 36ers within striking distance until the final minutes.The 36ers entered the last quarter of regulation holding a seven‑point lead and appeared poised to capture their first title since 2002. However, Davis sank a crucial basket with 30 seconds left, and Tim Soares’s tip‑in forced a 95‑95 tie with six seconds remaining, sending the game into overtime.During the extra period, Davis set the tone by stealing the ball early and adding seven more points, while 36ers forward Nick Rakocevic fouled out after a contested play. The Kings built a decisive 13‑point advantage, highlighted by Makuach Maluach’s emphatic dunk in the final minute.The triumph also marks the first championship for the Kings since legendary coach Brian Goorjian returned to revitalize the club last season, fulfilling expectations after a season highlighted by a record‑breaking 44‑point Game 1 win.For Adelaide, the loss ends a heart‑breaking campaign that saw the 36ers rally from a heavy Game 1 defeat to level the series twice, only to fall short of ending their 24‑year title drought.

Peptides are short chains of amino acids that naturally occur in the body, acting as hormones such as insulin, oxytocin and vasopressin, or as fragments released during protein digestion.In recent years, a wave of interest has turned these molecules into purported therapeutic agents for everything from weight loss to anti‑ageing and tissue repair. Prescription drugs like semaglutide (Wegovy) and tirzepatide (Mounjaro) are synthetic peptides that have undergone rigorous clinical testing and are approved for specific medical uses.However, a large portion of the market consists of unregulated, experimental peptides sold for self‑administration. These products often bypass the strict approval processes required for medicines, raising serious safety concerns.Who is using these products? Initially confined to a niche of powerlifters and bodybuilders in the 2010s, the audience has expanded dramatically. Influential figures such as podcaster Joe Rogan have promoted combinations like the “Wolverine stack” (BPC‑157 and TB‑500) for injury recovery, while other compounds—CJC‑1295, MK‑677, ipamorelin, and GHK‑Cu—are marketed for muscle growth and anti‑ageing. Social media platforms are now flooded with instructions on purchasing and injecting these substances.Scientific backing is scant. Reviews of the literature reveal that most experimental peptides have only been tested in animal or cell models. For example, BPC‑157 shows promise for tendon and muscle repair in pre‑clinical studies, but no randomized human trials have validated these effects. Similarly, TB‑4 and its synthetic analogue TB‑500 have demonstrated limited blood‑vessel formation in laboratory settings, yet human data are absent and both are listed as prohibited substances by the World Anti‑Doping Agency.Researchers also highlight a critical knowledge gap: dosage, frequency and treatment duration remain undefined, making self‑administration a gamble.Legal landscape in the UK is clear that peptides not classified as medicines fall outside the Medicines and Healthcare products Regulatory Agency’s (MHRA) remit. If a seller makes medicinal claims, the product must hold a marketing authorisation under the Human Medicines Regulations 2012. The MHRA warns that labeling items as “research use only” does not shield vendors from enforcement when evidence shows the products are intended for human consumption.Health risks are multi‑fold. Experts caution that benefits observed in animal studies do not guarantee safety in humans. Contamination with harmful impurities or bacterial endotoxins can trigger severe reactions, including septic shock. Injecting excess natural peptides may disrupt the body’s tightly regulated hormonal balance, potentially affecting multiple physiological pathways.There is also theoretical concern that augmenting peptide levels could accelerate tumour growth, as some cancers over‑express certain peptide pathways. While no direct cases have been documented, the possibility underscores the need for caution.Additional dangers include improper injection techniques (e.g., air embolism), unknown interactions with existing medications, and the lack of systematic monitoring of long‑term effects. As one researcher put it, “If something goes wrong, users may never notice until irreversible damage has occurred.”

The UK medicines regulator has opened an inquiry into a growing number of clinics that sell injectable peptides while promoting them as cures for everything from ageing to injury recovery. The investigation, disclosed by the Guardian, focuses on whether these businesses are breaching the Human Medicines Regulations 2012 by making unauthorised medicinal claims. Interest in peptide‑based treatments has surged in recent years, driven by social‑media influencers, some healthcare professionals, and direct‑to‑consumer marketers. Yet the scientific foundation for most of these claims is weak, with the bulk of research confined to animal models or cell‑culture studies. According to an MHRA spokesperson, any clinic that advertises a peptide as having therapeutic benefits must treat the product as a medicine, which triggers a comprehensive regulatory framework. "If clinics offering peptide injections make medicinal claims for those treatments, the products will be considered medicines and subject to regulation," the agency warned, adding that it will act against any identified breaches. Guardian reporters identified several high‑ranking Google search results that list peptides such as Cortexin (promoted for neuroprotection), BPC‑157 (claimed to aid tissue repair), and Thymosin Alpha (advertised to boost immunity). After being contacted, one clinic removed the statements from its website. Another clinic, while acknowledging the limited human evidence, continued to market seven specific peptides, providing price lists (£350 per month for a single peptide, £450 for two) and offering delivery via vials, syringes, or pre‑filled pens for an additional fee. During a free consultation, a clinician highlighted the experimental nature of the products, noting the absence of large‑scale, randomised clinical trials and recommending a break of four to eight weeks between treatment cycles to mitigate unknown risks. The clinician suggested BPC‑157 for post‑exercise recovery, describing it as a facilitator of cellular repair and blood flow, but warned against its use in smokers or individuals with a family history of cancer due to potential angiogenic effects. The second peptide discussed was MOTS‑C, portrayed as a mitochondrial enhancer that could improve stress resilience, lower insulin resistance, and reduce visceral fat by boosting cellular energy production (ATP). The MHRA confirmed it is reviewing whether the clinician’s statements constitute medicinal claims. The clinic defended its approach, emphasizing that it clearly informs clients that the peptides are not licensed medicines and that the evidence base is largely pre‑clinical. In a broader statement, Lynda Scammell, head of borderline products at the MHRA, explained that peptide products may be marketed as cosmetics, supplements, or medicines, and each case is assessed on its intended use, pharmacological effect, and supporting evidence. She added, "We disregard claims that products are for ‘research purposes’ if it is clear that such claims are being used as an attempt to avoid medicines regulations." Peptides are short chains of amino acids, some of which occur naturally (e.g., insulin). While synthetic peptide analogues like semaglutide and tirzepatide have secured approval for weight‑loss treatments, many of the compounds promoted by these clinics remain experimental and lack the rigorous safety and efficacy testing required for medicinal products.

The UK is facing a potential rebranding of its beloved breakfast spread, marmalade, due to new EU rules. The proposed changes are part of a planned food deal with the EU, which would require the UK to align with the bloc's naming rules for food products.Under the new rules, marmalades may need to be relabelled to specify the type of fruit used, such as 'citrus marmalade'. However, the government has clarified that 'orange marmalade' will still be allowed and that jars on UK shelves will remain unchanged.The Conservative former home secretary, Priti Patel, has accused Labour of 'attacking the great British marmalade', claiming that the prime minister is 'desperate to fit in with his EU pals and unpick Brexit'. However, the government spokesperson has denied this, stating that the deal simply supports trade by cutting unnecessary red tape.The UK is being asked to align with regulations already in force within the EU, which allow all conserves to be marketed as marmalades as long as the type of fruit is specified. The rules were relaxed in 2004 to allow fruit-based spreads to be referred to as marmalades in certain European countries.A government source pointed out that marmalade on UK supermarket shelves is already usually labelled as 'orange marmalade', which they suggested is in compliance with the EU rules. The government has assured that the agreement supports exporters while fully preserving the UK's ability to shape food rules in the national interest.

The Shift from Silent Infrastructure to Political FlashpointFor years, data centers operated as the silent backbone of the digital economy, largely unnoticed by the communities they served. However, recent polling data suggests this era of quiet expansion is ending. A growing wave of local opposition is turning data centers into a contentious political issue, forcing tech companies to confront the reality that their infrastructure is no longer welcome in everyone's backyard.Discrepancies in Public Sentiment: Harvard/MIT vs. QuinnipiacThe debate is split, with conflicting data highlighting the complexity of public opinion. A Harvard/MIT poll conducted in November offers a moderate view, finding that 40% of respondents supported the construction of a data center in their area. However, this support drops significantly when compared to industrial facilities, with 32% opposing the idea.Harvard/MIT Poll (Nov): 40% support data centers; 32% oppose.Quinnipiac Poll (March): 65% oppose AI data centers; 24% support.A fascinating insight from the Axios report notes that public preference shifts dramatically based on the facility type: more people would rather have an e-commerce warehouse than a data center.The Economic Trade-off: Jobs vs. Power CostsThe core of the conflict lies in the perceived benefits and drawbacks of these facilities. While data centers promise economic growth, a significant portion of the population is skeptical. Two-thirds of respondents in the Harvard/MIT survey expressed concern that a new data center would nudge electricity prices higher.Conversely, e-commerce warehouses are viewed more favorably, likely due to the tangible promise of local jobs and economic stimulation. However, analysts warn that this sentiment may be short-lived, as most data center projects employ very few people once operational, unlike the labor-intensive nature of warehousing.From Local Zoning to National Policy: The Future of Data Center RegulationThe divergence in polling numbers—from the moderate 40% support to the sharp 65% opposition—suggests that the data center debate is far from settled. As these facilities continue to proliferate, the discontent is likely to spill over into politics.With the "quiet" era of data center expansion effectively over, we can expect a surge in local zoning battles and potential federal regulation aimed at managing the energy consumption and community impact of AI infrastructure.

The recent visit of Anthropic's CEO Dario Amodei to Canberra has sparked a critical examination of the role of AI in society. Amodei, known for his 'progressive' approach to AI, has been promoting a vision of a future where AI transforms the economy and improves lives. However, the author of the article argues that this vision may not be as progressive as it seems. The risks associated with AI, such as job displacement, cultural homogenization, and potential harm to individuals, cannot be ignored. The article highlights the concerns of experts like Toby Walsh, who notes that AI is both good and bad, and that its impact depends on how it is used and regulated. The author, Peter Lewis, questions his own progressive credentials and argues that the unchecked development of AI threatens to undermine the very notion of progress. He suggests that the government should slow down the development of AI and establish guardrails to prevent its negative consequences. The article cites examples of experts and politicians, such as Bernie Sanders and Alexandria Ocasio-Cortez, who are calling for a moratorium on the development of new datacenters. The author argues that this cautious approach is necessary to ensure that AI is developed in a way that benefits society as a whole, rather than just a select few. Ultimately, the article concludes that the future of AI must be shaped by a nuanced and informed discussion about its potential risks and benefits. The author argues that only by slowing down the development of AI and establishing clear regulations can we ensure that its impact is truly progressive.

A US court has dismissed a lawsuit from WhatsApp's former security chief, who alleged that parent company Meta ignored internal flaws he flagged about the messaging app's digital defenses.Abdullah Baig, who claims he was fired in retaliation for raising these concerns, had alleged that billions of users had been put at risk because of these vulnerabilities. Thousands of employees could view sensitive user data, including profile photos and location, Baig claimed in the lawsuit filed in September. A judge ruled he had not presented enough evidence to move forward.The US district court in northern California ruled last month to dismiss Baig's claims, with the judge, Laurel Beeler, writing on 19 March that 'the complaint does not contain sufficient facts to show that the plaintiff reported violations of SEC rules or regulations.'Baig was head of WhatsApp's security division from 2021 to 2025. He said he had expressed concerns about cybersecurity issues to his supervisor five times but was ignored; he also said he wrote directly to Meta's CEO, Mark Zuckerberg, about what he saw as a violation of US Securities and Exchange Commission rules and escalating retaliation against him. He also claimed that the company didn't fix the hacking of more than 100,000 accounts daily – and focused instead on user growth. At the time, WhatsApp said in a statement that he was 'a former employee dismissed for poor performance' who had filed a suit based on distorted claims.A WhatsApp spokesperson said: 'This ruling reaffirms what we've said all along: These claims have no merit. We're proud of our strong record of protecting people's privacy and security, and will continue building on it.'Baig's lawyer suggested in a statement emailed to the Guardian that the legal fight was not over. 'Mr Baig is not done fighting for users,' said Wilmer Harris, who represents Baig. 'The judge dismissed on pleading grounds, not merit, and we look forward to addressing those deficiencies and ensuring Meta has to finally engage with the substance of Mr Baig's allegations.'

The US government has taken legal action against Illinois for attempting to regulate the rapidly growing online prediction market industry. The lawsuit, filed in Chicago federal court, claims that Illinois' efforts to shut down so-called designated contract markets regulated by the Commodity Futures Trading Commission (CFTC) are unlawful.Online prediction markets allow users to bet on a wide range of events, from Oscar winners to military conflicts. These platforms classify their offerings as 'event derivatives,' which fall under federal commodities law and are overseen by the CFTC. This classification allows them to operate in all 50 states for users 18 and older.Illinois introduced legislation earlier this year that would impose strict regulations on prediction markets, including an effective ban on sports-related trades, advertising restrictions, and age verification measures. The CFTC argues that this legislation intrudes on its exclusive authority to regulate national swaps markets.The lawsuit is the first by the CFTC to block state gaming regulators from policing operators of prediction markets. It cites cease-and-desist letters sent by the Illinois gaming board to companies like Kalshi, Polymarket, and Crypto.com, alleging violations of Illinois gambling laws.The federal lawsuit names Illinois Governor JB Pritzker and Illinois Attorney General Kwame Raoul as defendants. The case highlights the ongoing debate over the regulation of prediction markets, with some arguing they are essentially gambling operations and others seeing them as federally regulated financial exchanges.Congress is also considering federal measures to regulate prediction markets, including a bipartisan bill introduced by US senators that would ban federally regulated platforms from allowing wagers on sporting events.

The author spent a month testing Meta's smartglasses, which feature an integrated AI assistant voiced by Judi Dench. The glasses can take photos, provide directions, and answer questions, but the author found them to be unreliable and frustrating to use.The glasses raise significant privacy concerns, with the author noting that they can be used for covert recording and that people may not be aware when they are being filmed. The author also experienced creepy feelings while wearing the glasses, particularly when they were used to record strangers without their consent.The author concludes that while smartglasses have the potential to be useful assistive technology for people with disabilities, they are not yet reliable or functional enough to be widely adopted. The author also notes that Meta's plans for facial recognition and data collection raise significant concerns about privacy and surveillance.Experts warn that smartglasses may become a flashpoint in a bigger, existential discussion about how much integration we want with technology, and that regulation is needed to protect bystanders' privacy. The author ultimately decides that the glasses are not worth the risks and drawbacks, and that people should think carefully before adopting this technology.